#USA #Denver #GenoPATHx #QuantiPath.bio #Michael Connolly

QuantiPath Strengthens Executive Team Ahead of GenoPATHx Launch

QuantiPath.bio, a pioneering biotechnology company committed to enhancing food safety through advanced genetic diagnostics, has recently announced the enhancement of its leadership team with the addition of two prominent executives. Michael Connolly will join as General Counsel, while Janine Williams will take on the role of Chief Marketing Officer. These strategic moves build the foundation needed for the commercial debut of QuantiPath's flagship product, GenoPATHx.

New Executive Appointments

Michael Connolly, General Counsel

Michael Connolly brings a wealth of legal expertise, having amassed decades of experience across technology and biotechnology sectors. As QuantiPath's first General Counsel, Connolly will leverage his extensive background in intellectual property, regulatory compliance, and contract strategy. His role will be pivotal as the company navigates the intricate legal landscape of molecular diagnostics and prepares for global commercialization. Connolly's seasoned perspective will be essential in ensuring that QuantiPath adheres to industry standards and regulations.

Janine Williams, Chief Marketing Officer

Joining QuantiPath as Chief Marketing Officer, Janine Williams comes with a distinguished reputation for launching disruptive brands within the tech industry. Williams’ experience in brand strategy, commercialization, and customer experience design is expected to play a crucial role in the upcoming launch of GenoPATHx. Recently, she led the rebranding of QuantiPath from its previous identity as Food Supply Security and will now spearhead the marketing and communication campaigns for the company’s flagship offering.

The Importance of Leadership

John LoPorto, President and CEO of QuantiPath, emphasized the need for strong leadership as the company approaches its market introduction, stating, “As we prepare for our commercial debut, our leadership needs to reflect the ambition and complexity of what we are bringing to market.” LoPorto noted that both Connolly and Williams are well-respected figures in their fields, bringing invaluable legal rigor and marketing insight that will propel QuantiPath to new heights in the industry.

About GenoPATHx

QuantiPath’s flagship product, GenoPATHx, is designed as a next-generation PCR-based assay capable of detecting, differentiating, and quantifying over 60 serovars of Salmonella. What sets GenoPATHx apart is its ability to distinguish between wild-type and vaccine strains, providing an unmatched level of diagnostic power. This innovative technology is positioned to deliver real-time insights to food producers, veterinary labs, and regulatory agencies, ultimately enhancing food safety and public health.

A Committed Team

The new leadership additions come as part of QuantiPath’s broader strategy to combine scientific excellence with operational leadership. The expanded executive team includes notable figures such as:

• - Jon LoPorto - President and CEO
• - Tim Krebs - Chief Financial Officer
• - Lisa Leier, PhD - Chief Science Officer
• - Elizabeth Krushinskie, DVM, PhD - Vice President, Poultry Sector
• - Jens Kjaer, DVM - Director, Livestock Sector
• - Scott Sherod - Director, Operations

This collective expertise positions QuantiPath to effectively scale its operations as it works towards its mission of delivering clarity, speed, and actionable insights in the spheres of food safety and animal health.

Looking Forward

With their fresh approach and strong leadership, QuantiPath is set to redefine the standards of food safety testing, empowering organizations from farm to fork. As the demand for rigorous food safety measures grows, the introduction of GenoPATHx is poised to become a game-changer, ensuring consumer safety and operational confidence across the food industry. Further details can be found on QuantiPath's website and their updates on LinkedIn.